In vitro viability of human cavernosal endothelial and fibroblastic cells after exposure to papaverine/phentolamine and prostaglandin E1

BJU International

Volumn 95, Issue 9, 2005, Pages 1351-1357

  Pilatz, Adrian ^a   Schultheiss, Dirk ^a   Gabouev, Alexander I ^a   Schlote, Norbert ^a   Mertsching, Heike ^a   Jonas, Udo ^a   Stief, Christian G ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cell culture; Corpus cavernosum; Intracavernosal; Papaverine; Phentolamine; Prostaglandin E1

Indexed keywords

PAPAVERINE; PROSTAGLANDIN E1; VASOACTIVE AGENT;

ACIDITY; ADOLESCENT; ADULT; ARTICLE; CELL COUNT; CELL CULTURE; CELL METABOLISM; CELL REGENERATION; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DILUTION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EXPOSURE; ENDOTHELIUM; ERECTILE DYSFUNCTION; FIBROBLAST; HUMAN; HUMAN TISSUE; INTERSTITIUM; MALE; PENILE FIBROSIS; PENIS; PRIORITY JOURNAL; RISK FACTOR;

ALPROSTADIL; CELL SURVIVAL; CELLS, CULTURED; ENDOTHELIAL CELLS; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; PAPAVERINE; PENIS; PHENTOLAMINE; PHOSPHODIESTERASE INHIBITORS; VASODILATOR AGENTS;

EID: 20444390660     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05499.x     Document Type: Article

References (35)

1. Montorsi F, Salonia A, Zanoni M et al. Current status of local penile therapy. Int J Impot Res 2002; 14 (Suppl. 1): S70-81
2. Bechara A, Casabe A, Cheliz G, Romano S, Fredotovich N. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses. J Urol 1996; 155: 913-4
3. Govier FE, McClure RD, Weissman RM, Gibbons RP, Pritchett TR, Kramer-Levien D. Experience with triple-drug therapy in a pharmacological erection program. J Urol 1993; 150: 1822-4
4. Meinhardt W, Lycklama a Nijeholt AA, Kropman RF, Vermeij P, Zwartendijk J. Comparison of a mixture of papaverine, phentolamine and prostaglandin E1 with other intracavernous injections. Eur Urol 1994; 26: 319-21
5. McMahon CG, Samali R, Johnson H. Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol 1999; 162: 1992-7
6. Steers WD. Viability and safety of combination drug therapies for erectile dysfunction. J Urol 2003; 170: S20-3
7. Chew KK, Stuckey BG. Clinical course of penile fibrosis in intracavernosal prostaglandin E1 injection therapy: a follow-up of 44 patients. Int J Impot Res 2003; 15: 94-8
8. Porst H. The rationale for prostaglandin E1 in erectile failure. A survey of worldwide experience. J Urol 1996; 155: 802-15
9. Aboseif SR, Breza J, Bosch RJ et al. Local and systemic effects of chronic intracavernous injection of papaverine, prostaglandin E1, and saline in primates. J Urol 1989; 142: 403-8
10. Abozeid M, Juenemann KP, Luo JA, Lue TF, Yen TS, Tanagho EA. Chronic papaverine treatment, the effect of repeated injections on the simian erectile response and penile tissue. J Urol 1987; 138: 1263-6
11. Hwang TI, Yang CR, Ho WL, Chu HW. Histopathological change of corpora cavernosa after long-term intracavernous injection. Eur Urol 1991; 20: 301-6
12. Sahin M, Basar MM, Bozdogan O, Atan A. Short-term histopathologic effects of different intracavernosal agents on corpus cavernosum and antifibrotic activity of intracavernosal verapamil: an experimental study. Urology 2001; 58: 487-92
13. Stackl W, Loupal G, Holzmann A. Intracavernous injection of vasoactive drugs in the rabbit. Urol Res 1988; 16: 455-8
14. Wespes E, Sattar AA, Noel JC, Schulman CC. Does prostaglandin E1 therapy modify the intracavernous musculature? J Urol 2000; 163: 464-6
15. Bivalacqua TJ, Usta MF, Champion HC, Kadowitz PJ, Hellstrom WJ. Endothelial dysfunction in erectile dysfunction, role of the endothelium in erectile physiology and disease. J Androl 2003; 24: S17-37
16. Schultheiss D, Badalyan R, Pilatz A et al. Androgen and estrogen receptors in the human corpus cavernosum penis: immunohistochemical and cell culture results. World J Urol 2003; 21: 320-4
17. van Ahlen H, Peskar BA, Sticht G, Hertfelder HJ. Pharmacokinetics of vasoactive substances administered into the human corpus cavernosum. J Urol 1994; 151: 1227-30
18. Rajasekaran M, Pagnon V, Monga M. Vasoactive agents induce cytotoxicity in cultured human penile smooth muscle cells. Urology 2002; 59: 155-8
19. da Costa AO, de Assis MC, Marques Ede A, Plotkowski MC. Comparative analysis of three methods to assess viability of mammalian cells in culture. Biocell 1999; 23: 65-72
20. Kato M, Makino S, Kimura H, Ota T, Furuhashi T, Nagamura Y. Evaluation of mitochondrial function and membrane integrity by dual fluorescent staining for assessment of sperm status in rats. J Toxicol Sci 2002; 27: 11-8
21. Bhargava G, Valcic M, Melman A. Human corpora cavernosa smooth muscle cells in culture, influence of catecholamines and prostaglandins on cAMP formation. Int J Impotence Res 1990; 2: 35-6
22. Cummings BS, Zangar RC, Novak RF, Lash LH. Cytotoxicity of trichloroethylene and S-(1,2-dichlorovinyl)-L-cysteine in primary cultures of rat renal proximal tubular and distal tubular cells. Toxicology 2000; 150: 83-98
23. Granchi S, Vannelli GB, Vignozzi L et al. Expression and regulation of endothelin-1 and its receptors in human penile smooth muscle cells. Mol Hum Reprod 2002; 8: 1053-64
24. Wang HZ, Chang CH, Lin CP, Tsai MC. Using MTT viability assay to test the cytotoxicity of antibiotics and steroid to cultured porcine corneal endothelial cells. J Ocul Pharmacol Ther 1996; 12: 35-43
25. van Ahlen H, Piechota HJ, Hermanns M, Krüger E. Metabolic changes in the human corpus cavernosum under vasoactive substances. Int J Impot Res 1990; 2 (Suppl. 2): 244
26. Seidmon EJ, Samaha AM Jr. The pH analysis of papaverine-phentolamine and prostaglandin E1 for pharmacologic erection. J Urol 1989; 141: 1458-9
27. Stackl W, Stief CG, Benard F et al. Intracavernous injection of solutions with different osmolarity and pH in the rabbit. Int J Impot Res 1989; 1: 197-200
28. Gao YJ, Stead S, Lee RM. Papaverine induces apoptosis in vascular endothelial and smooth muscle cells. Life Sci 2002; 70: 2675-85
29. Brown SL, Haas CA, Koehler M, Bodner DR, Seftel AD. Hepatotoxicity related to intracavernous pharmacotherapy with papaverine. Urology 1998; 52: 844-7
30. Cooper GJ, Gillot T, Parry EA, Kennedy A, Wilkinson GA. Papaverine injures the endothelium of the internal mammary artery. Cardiovasc Surg 1995; 3: 553-5
31. Gao YJ, Yang H, Teoh K, Lee RM. Detrimental effects of papaverine on the human internal thoracic artery. J Thorac Cardiovasc Surg 2003; 126: 179-85
32. Cattaneo MG, Pola S, Deho V, Sanguini AM, Vicentini LM. Alprostadil suppresses angiogenesis in vitro and in vivo in the murine Matrigel plug assay. Br J Pharmacol 2003; 138: 377-85
33. Deng DY, Lin G, Bochinski D, Lin CS, Lue TF. Effect of prostaglandin E1 on angiogenesis and neural growth. J Urol 2003; 169 (Suppl.): 313
34. Mehrabi MR, Serbecic N, Tamaddon F et al. Clinical and experimental evidence of prostaglandin E1-induced angiogenesis in the myocardium of patients with ischemic heart disease. Cardiovasc Res 2002; 56: 214-24
35. Moreland RB, Traish A, McMillin MA, Smith B, Goldstein I, Saenz de Tejada I. PGE1 suppresses the induction of collagen synthesis by transforming growth factor-beta 1 in human corpus cavernosum smooth muscle. J Urol 1995; 153: 826-34